Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multi-centre, Rollover Study to Characterise Long-term Safety and Efficacy of Etavopivat in Adults, Adolescents and Children Who Have Sickle Cell Disease or Thalassaemia and Have Completed a Treatment Period in an Etavopivat Study

NCT06609226 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT06609226
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06609226 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multi-centre, Rollover Study to Characterise Long-term Safety and Efficacy of Etavopivat in Adults, Adolescents and Children Who Have Sickle Cell Disease or Thalassaemia and Have Completed a Treatment Period in an Etavopivat Study
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Recruiting
Start date
January 10, 2025
Completion date
December 30, 2030
Enrollment
480 (estimated)
Sites
107

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell disease, thalassemia